RestorGenex Corp 4

Accession 0001437749-16-023552

$CRVOCIK 0001053691operating

View on SEC.gov Company Profile

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 7:53 PM ET

Size

25.1 KB

Accession

0001437749-16-023552

Insider Transaction Report

Form 4

Period: 2016-01-08

RestorGenex CorpRESX

Byrne Thomas E

General Counsel

Transactions

Award
Stock Option (Right to Buy)
2016-01-08+91,316→ 91,316 total
Exercise: $0.22Exp: 2022-10-09→ Common Stock (91,316 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+182,632→ 182,632 total
Exercise: $0.42Exp: 2024-12-01→ Common Stock (182,632 underlying)
Award
Common Stock
2016-01-08+1,391,867→ 1,391,867 total
Award
Stock Option (Right to Buy)
2016-01-08+109,579→ 109,579 total
Exercise: $0.22Exp: 2022-10-09→ Common Stock (109,579 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+182,632→ 182,632 total
Exercise: $0.62Exp: 2023-10-05→ Common Stock (182,632 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+365,265→ 365,265 total
Exercise: $0.55Exp: 2025-10-30→ Common Stock (365,265 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+215,506→ 215,506 total
Exercise: $0.22From: 2012-05-17Exp: 2022-05-17→ Common Stock (215,506 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+36,526→ 36,526 total
Exercise: $0.35Exp: 2023-10-05→ Common Stock (36,526 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+182,632→ 182,632 total
Exercise: $0.42Exp: 2024-12-01→ Common Stock (182,632 underlying)
Award
Stock Option (Right to Buy)
2016-01-08+237,422→ 237,422 total
Exercise: $0.55Exp: 2025-10-30→ Common Stock (237,422 underlying)

Footnotes (7)

[F1]Received in exchange for 381,056 units of Diffusion Pharmaceuticals LLC ("Diffusion") in connection with the consummation of the merger (the "Merger") of Diffusion and a wholly-owned subsidiary of the Issuer ("Merger Sub") on January 8, 2016 based upon the exchange rate set forth in the Agreement and Plan of Merger, dated December 15, 2015, by and among the Issuer, Diffusion and Merger Sub.
[F2]In connection with the consummation of the Merger, an option originally granted on May 17, 2012 to purchase membership units in Diffusion was converted into an option to purchase common stock of the Issuer.
[F3]In connection with the consummation of the Merger, an option originally granted on October 9, 2012 to purchase membership units in Diffusion was converted into an option to purchase common stock of the Issuer.
[F4]The shares underlying the options vest in equal parts each month until fully vested on the third anniversary of the grant date.
[F5]In connection with the consummation of the Merger, an option originally granted on October 5, 2013 to purchase membership units in Diffusion was converted into an option to purchase common stock of the Issuer.
[F6]In connection with the consummation of the Merger, an option originally granted on December 1, 2014 to purchase membership units in Diffusion was converted into an option to purchase common stock of the Issuer.
[F7]In connection with the consummation of the Merger, an option originally granted on October 30, 2015 to purchase membership units in Diffusion was converted into an option to purchase common stock of the Issuer.

Documents

1 file

4
rdgdoc.xmlPrimary
FORM 4

Issuer

RestorGenex Corp

CIK 0001053691

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001053691

Filing Metadata

Form type: 4
Filed: Jan 11, 7:00 PM ET
Accepted: Jan 12, 7:53 PM ET
Size: 25.1 KB

View on SEC.gov